Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG

被引:13
|
作者
Palmowski-Wolfe A.M. [1 ]
Perez M.T. [1 ,2 ]
Behnke S. [2 ]
Fuss G. [2 ]
Martziniak M. [2 ]
Ruprecht K.W. [1 ]
机构
[1] Department of Ophthalmology, University of Saarland
[2] Department of Neurology, University of Saarland
关键词
Dopamine; M-sequence; MfERG; Multifocal stimulation techniques; Parkinson;
D O I
10.1007/s10633-006-0008-8
中图分类号
学科分类号
摘要
Purpose: In animal studies intravitreal injection of tetrodotoxin (TTX) results in mfERG waveform changes similar to those observed in glaucoma. As TTX blocks amacrine as well as ganglion cells, there is still a question regarding the underlying cell population responsible for these changes in waveform. In an attempt to assess the contribution of the amacrine cells to these changes, a mfERG was obtained from patients with Parkinson's disease as some amacrine cells are mediated by dopamine, a substance lacking in Parkinson's. Methods: Eight patients with early Parkinson's disease underwent ophthalmologic examination, testing of contrast sensitivity and electrophysiological examination according to ISCEV standard at least 12 h following their last medication with Dopamine. A slow stimulation mfERG was obtained with a stimulus base interval of 53.3 ms and with a stimulus base interval of 106.6 ms. During MF-ERG recordings 103 hexagons stimulated the central 50 deg of the retina simultaneously and independently (m-sequence 213, Lmax: 200 cd/m2,-100% contrast). Results: Contrast sensitivity and ISCEV standard electrophysiological testing was unremarkable. When the mfERG was analyzed, only four patients had an adequate signal-to-noise ratio to allow further data analysis - one of whom was diagnosed with a multi system atrophy in retrospect. The first order response component was analyzed at a filter setting of 10-300 Hz and at 100-300 Hz (OPs) and compared to mfERGs of a control group. On average, in patients, the amplitude of N1P1 was slightly lower in the central and nasal response averages. When the three OPs at a latency of 72-89 ms were analyzed in the 53.3 ms base interval recording, the most marked difference in amplitude was observed in the superior nasal response average of the first OP. Here a mean amplitude of 1.3 nV/deg2 in patients compared to a mean amplitude of 1.9 nV/deg2 in the control group (P: 0.08). Discussion: In contrast to our previous findings in NTG, there was a consistent presence of three OPs. Under the stimulus conditions applied, we did not find an influence of dopaminergic amacrine cells on the mfERG in our patients with moderate stages of Parkinsion's. The difficulties in obtaining an adequate signal-to noise ratio due to e.g. muscle artifacts even in Parkinson patients of moderate disease stages render a success of mfERG recording in patients with more advanced stages unlikely. The question of the influence of dopaminergic amacrine cells on the mfERG could possibly be addressed using MPDT in animal research. © Springer 2006.
引用
收藏
页码:209 / 215
页数:6
相关论文
共 50 条
  • [1] A Comparison of the Fast Stimulation Multifocal-ERG in Patients with an IOL and Control Groups of Different Age
    Anja M. Palmowski-Wolfe
    Ursula Woerdehoff
    Documenta Ophthalmologica, 2005, 111 : 87 - 93
  • [2] Influence of dopamine deficiency on interhemispheric crosstalk in Parkinson's disease
    Loehrer, P.
    Nettersheim, F.
    Weber, I.
    Jung, F.
    Timmermann, L.
    MOVEMENT DISORDERS, 2018, 33 : S778 - S778
  • [3] A comparison of the fast stimulation multifocal-ERG in patients with an IOL and control groups of different age
    Palmowski-Wolfe, AM
    Woerdehoff, U
    DOCUMENTA OPHTHALMOLOGICA, 2005, 111 (02) : 87 - 93
  • [4] Continuous dopamine-receptor stimulation in early Parkinson's disease
    Olanow, CW
    Schapira, AHV
    Rascol, O
    TRENDS IN NEUROSCIENCES, 2000, 23 (10) : S117 - S126
  • [5] Simultaneous recordings of slow-stimulation multifocal ERG and multifocal VEP in normal tension glaucoma.
    Allgayer, RJ
    Palmowski, AM
    Heinemann-Vernaleken, B
    Ruprecht, KW
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S561 - S561
  • [6] Dopamine agonist therapy in early Parkinson's disease
    Stowe, R. L.
    Ives, N. J.
    Clarke, C.
    van, Hilten J.
    Ferreira, J.
    Hawker, R. J.
    Shah, L.
    Wheatley, K.
    Gray, R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
  • [7] The role of dopamine agonists in early Parkinson's disease
    Watts, RL
    NEUROLOGY, 1997, 49 (01) : S34 - S48
  • [8] Dopamine agonists in the treatment of early Parkinson's disease
    Rinne, UK
    NEUROPROTECTION AND NEURODEGENERATION IN PARKINSON'S DISEASE, 2000, (71): : 33 - 37
  • [9] Dopamine agonist monotherapy in early Parkinson's disease
    Clarke, CE
    HOSPITAL MEDICINE, 2003, 64 (01): : 8 - 11
  • [10] Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease
    Lang, AE
    Obeso, JA
    ANNALS OF NEUROLOGY, 2004, 55 (06) : 761 - 765